These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15886399)

  • 1. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro.
    Wang Z; Foye A; Chang Y; Chess PR; Wright TW; Bhagwat S; Gigliotti F; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2005 Jun; 288(6):L1124-31. PubMed ID: 15886399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D.
    Atochina EN; Beck JM; Scanlon ST; Preston AM; Beers MF
    J Lab Clin Med; 2001 Jun; 137(6):429-39. PubMed ID: 11385364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant.
    Atochina EN; Beers MF; Scanlon ST; Preston AM; Beck JM
    Am J Physiol Lung Cell Mol Physiol; 2000 Mar; 278(3):L599-609. PubMed ID: 10710533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of different hydrophobic constituents in the adsorption of pulmonary surfactant.
    Wang Z; Hall SB; Notter RH
    J Lipid Res; 1996 Apr; 37(4):790-8. PubMed ID: 8732779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice.
    Beers MF; Atochina EN; Preston AM; Beck JM
    J Lab Clin Med; 1999 May; 133(5):423-33. PubMed ID: 10235125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.
    Wang Z; Schwan AL; Lairson LL; O'Donnell JS; Byrne GF; Foye A; Holm BA; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2003 Sep; 285(3):L550-9. PubMed ID: 12902318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
    Sheehan PM; Stokes DC; Yeh YY; Hughes WT
    Am Rev Respir Dis; 1986 Sep; 134(3):526-31. PubMed ID: 3489425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function.
    Wang Z; Schwab U; Rhoades E; Chess PR; Russell DG; Notter RH
    Tuberculosis (Edinb); 2008 May; 88(3):178-86. PubMed ID: 18155644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary importance of zwitterionic over anionic phospholipids in the surface-active function of calf lung surfactant extract.
    Wang Z; Gurel O; Weinbach S; Notter RH
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1049-57. PubMed ID: 9351602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant.
    Walther FJ; Waring AJ; Hernandez-Juviel JM; Gordon LM; Schwan AL; Jung CL; Chang Y; Wang Z; Notter RH
    PLoS One; 2007 Oct; 2(10):e1039. PubMed ID: 17940603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
    Wang Z; Chang Y; Schwan AL; Notter RH
    Am J Respir Cell Mol Biol; 2007 Oct; 37(4):387-94. PubMed ID: 17556674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple mechanisms of lung surfactant inhibition.
    Holm BA; Wang Z; Notter RH
    Pediatr Res; 1999 Jul; 46(1):85-93. PubMed ID: 10400140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical activity of synthetic phospholipids combined with purified lung surfactant 6000 dalton apoprotein.
    Notter RH; Shapiro DL; Ohning B; Whitsett JA
    Chem Phys Lipids; 1987 Jun; 44(1):1-17. PubMed ID: 3607971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.
    Wright TW; Notter RH; Wang Z; Harmsen AG; Gigliotti F
    Infect Immun; 2001 Feb; 69(2):758-64. PubMed ID: 11159965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additivity of protein and nonprotein inhibitors of lung surfactant activity.
    Wang Z; Notter RH
    Am J Respir Crit Care Med; 1998 Jul; 158(1):28-35. PubMed ID: 9655703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Content of dipalmitoyl phosphatidylcholine in lung surfactant: ramifications for surface activity.
    Holm BA; Wang Z; Egan EA; Notter RH
    Pediatr Res; 1996 May; 39(5):805-11. PubMed ID: 8726232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
    Holm BA; Notter RH
    J Appl Physiol (1985); 1987 Oct; 63(4):1434-42. PubMed ID: 3693177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.
    Hoffman AG; Lawrence MG; Ognibene FP; Suffredini AF; Lipschik GY; Kovacs JA; Masur H; Shelhamer JH
    Chest; 1992 Dec; 102(6):1730-6. PubMed ID: 1446480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro--comparison to natural surfactant.
    Seeger W; Thede C; Günther A; Grube C
    Biochim Biophys Acta; 1991 Jan; 1081(1):45-52. PubMed ID: 1991155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A.
    Zimmerman PE; Voelker DR; McCormack FX; Paulsrud JR; Martin WJ
    J Clin Invest; 1992 Jan; 89(1):143-9. PubMed ID: 1530850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.